peripher
blood
mononuclear
cell
pbmc
obtain
healthi
donor
allogen
hsct
recipi
inform
consent
baylor
colleg
medicin
institut
review
protocol
use
gener
hmpvdirect
virusspecif
cell
vst
phytohemagglutinin
pha
blast
pha
blast
gener
pbmc
cellsml
plate
use
pha
sigmaaldrich
st
loui
mo
maintain
vst
medium
roswel
park
memori
institut
hyclon
laboratori
logan
ut
click
irvin
scientif
santa
ana
ca
mm
glutamax
tmi
life
technolog
grand
island
ny
human
ab
serum
valley
biomed
winchest
va
supplement
interleukin
uml
nation
institut
health
bethesda
va
replenish
everi
day
pbmc
stimul
use
pepmix
peptid
librari
overlap
amino
acid
span
antigen
n
p
f
sh
g
l
deriv
hmpv
strain
hmpv
substrain
pepmix
synthes
jpt
peptid
technolog
berlin
germani
lyophil
pepmix
reconstitut
dimethyl
sulfoxid
sigmaaldrich
st
loui
mo
store
fifteen
million
freshfrozen
pbmc
pellet
tube
puls
minut
pepmix
concentr
pbmc
resuspend
vst
medium
supplement
uml
interleukin
ngml
interleukin
r
system
minneapoli
mn
plate
either
plate
cellswel
transfer
devic
devis
wilson
wolf
minneapoli
mn
medium
cytokin
replenish
day
cultur
split
reach
densiti
cellswel
plate
cell
devic
day
vst
harvest
count
use
phenotyp
function
studi
second
stimul
hmpvspecif
cell
plate
irradi
gy
pepmixpuls
autolog
pha
blast
cell
resuspend
ml
vst
medium
supplement
interleukin
interleukin
transfer
devic
day
day
cultur
replenish
fresh
medium
supplement
ngml
interleukin
cellgenix
freiburg
germani
day
vst
harvest
use
studi
hmpvspecif
cell
surfac
stain
monoclon
antibodi
becton
dickinson
bd
franklin
lake
nj
beckman
coulter
pasadena
ca
stain
cell
wash
phosphatebuff
salin
pb
sigma
aldrich
st
loui
mo
pellet
antibodi
ad
satur
amount
incub
minut
dark
cell
wash
twice
analyz
approxim
live
cell
acquir
gallio
flow
cytomet
beckman
coulter
brea
ca
data
analyz
use
kaluza
flow
cytometri
analysi
softwar
beckman
coulter
vst
harvest
resuspend
concentr
cellsml
vst
medium
plate
plate
cell
stimul
ng
test
control
pepmix
presenc
brefeldin
monensin
bd
overnight
subsequ
vst
wash
pb
pellet
surfac
stain
incub
minut
dark
wash
pellet
fix
permeabil
cytofixcytoperm
solut
bd
minut
dark
wash
pb
contain
fetal
bovin
serum
saponin
bd
cell
incub
interferon
tumor
necrosi
factor
antibodi
bd
minut
dark
cell
wash
twice
cold
pb
contain
fetal
bovin
serum
saponin
least
live
cell
popul
analyz
facscalibur
equip
gallio
softwar
data
analyz
use
kaluza
flow
cytometri
analysi
softwar
beckman
coulter
stain
perform
use
ebiosci
kit
per
manufactur
instruct
briefli
vst
rest
medium
without
cytokin
hour
cell
wash
pb
surfac
stain
antibodi
bd
minut
cell
wash
resuspend
ml
fixationpermeabil
buffer
incub
hour
dark
wash
pb
cell
resuspend
permeabil
buffer
incub
isotyp
antibodi
clone
minut
follow
final
wash
cell
acquir
analyz
facscalibur
data
analyz
use
kaluza
flow
cytometri
analysi
softwar
beckman
coulter
elispot
analysi
use
quantit
frequenc
antigenspecif
granzym
cell
pbmc
hmpvspecif
cell
resuspend
cellsml
respect
vst
medium
cell
ad
elispot
well
antigenspecif
activ
measur
direct
stimul
ngpeptideml
individu
hmpv
pepmix
n
p
f
sh
g
l
control
pepmix
n
f
respiratori
syncyti
viru
hn
parainfluenza
viru
type
cytomegaloviru
pha
staphylococc
enterotoxin
b
serv
posit
control
vst
pbmc
respect
unstimul
cell
serv
neg
control
condit
run
duplic
result
consid
posit
frequenc
reactiv
cell
spotform
cell
sfc
defin
potenc
threshold
hour
incub
plate
develop
previous
describ
dri
overnight
room
temperatur
dark
sent
zellnet
consult
new
york
ny
quantif
sfc
input
cell
number
plot
hmpvspecif
tcell
cytokin
profil
assess
use
milliplex
high
sensit
human
cytokin
panel
millipor
billerica
per
manufactur
instruct
total
vst
stimul
use
n
p
f
pepmix
ngpepmixwel
overnight
subsequ
supernat
collect
plate
duplic
well
incub
overnight
antibodyimmobil
bead
wash
plate
hour
room
temperatur
biotinyl
detect
antibodi
final
streptavidinphycoerythrin
ad
minut
room
temperatur
sampl
wash
analyz
luminex
xmap
technolog
use
xponent
softwar
measur
cytotox
specif
hmpvspecif
cell
standard
releas
assay
use
effector
target
ratio
vst
use
effector
target
autolog
pha
blast
puls
pepmix
autolog
pha
blast
alon
use
specif
control
percentag
specif
lysi
calcul
experiment
releas
spontan
releas
maximum
releas
spontan
releas
nasopharyng
wash
sampl
patient
upper
respiratori
tract
infect
bronchoalveolar
lavag
sampl
patient
lower
respiratori
tract
infect
test
hmpv
pathogen
includ
adenoviru
coronaviru
rhinovirusenteroviru
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
organ
use
multiplex
revers
transcript
polymeras
chain
reaction
assay
sampl
analyz
viracor
eurofin
diagnost
lee
summit
mo
houston
methodist
hospit
houston
tx
sinc
littl
known
tcell
respons
hmpv
isol
pbmc
healthi
donor
stimul
pepmix
span
viral
antigen
evalu
frequenc
antigenspecif
cell
circul
peripher
blood
use
elispot
assay
shown
figur
magnitud
activ
peripher
blood
low
exampl
donor
screen
age
rang
year
mean
age
error
mean
sem
year
detect
follow
mean
number
antigenreact
input
pbmc
n
p
f
sh
g
l
respect
magnitud
activ
similar
antigen
respiratori
syncyti
viru
genet
clinic
close
relat
famili
member
mean
antigenreact
input
pbmc
n
f
respect
n
parainfluenza
viru
type
mean
antigenreact
input
pbmc
hn
respect
n
substanti
less
respons
immunodomin
cytomegaloviru
antigen
mean
input
pbmc
respect
figur
determin
whether
appar
pauciti
hmpvreactiv
cell
peripher
blood
simpli
reflect
frequenc
cell
limit
detect
elispot
assay
perform
singl
vitro
stimul
assay
select
amplifi
specif
cell
thu
expos
pbmc
healthi
individu
age
rang
year
mean
age
year
mastermix
hmpv
peptid
librari
allow
reactiv
cell
expand
day
overal
achiev
mean
foldincreas
total
cell
number
n
figur
expand
popul
compris
cell
mix
cytotox
cell
helper
cell
figur
evid
regulatori
tcell
outgrowth
assess
stain
supplementari
figur
furthermor
expand
cell
express
central
mean
effector
mean
memori
marker
n
figur
next
determin
whether
enrich
hmpvreactiv
cell
assess
specif
elispot
assay
shown
figur
readili
abl
expand
popul
specif
antigen
except
fold
enrich
achiev
summar
figur
data
suggest
hmpvspecif
cell
resid
memori
pool
readili
amplifi
ex
vivo
sought
identifi
hierarchi
immunodomin
base
number
donor
posit
respond
antigen
cell
magnitud
respons
base
absolut
number
sfc
per
input
cell
tabl
f
recogn
donor
screen
induc
highest
frequenc
specif
cell
mean
input
cell
follow
descend
order
n
n
respect
n
p
n
l
n
g
n
reactiv
sh
detect
donor
screen
input
cell
wherea
immunogen
notabl
major
donor
screen
recogn
express
antigen
figur
thu
subsequ
function
studi
chose
focu
top
immunogen
target
antigen
f
n
p
evalu
whether
hmpv
specif
mediat
predominantli
andor
tcell
subset
perform
intracellular
cytokin
stain
studi
gate
cell
antigen
specif
determin
product
either
cytokin
detect
predominantli
tcell
compart
minor
compon
figur
show
fluorescenceactiv
cellsort
data
repres
donor
figur
summar
data
donor
studi
product
multipl
proinflammatori
cytokin
effector
molecul
report
correl
enhanc
cytolyt
function
improv
vivo
activ
thu
comprehens
explor
function
profil
expand
vst
found
major
cell
figur
also
produc
detail
result
donor
shown
figur
data
donor
summar
figur
furthermor
line
produc
granulocytemacrophag
colonystimul
factor
gmcsf
figur
well
granzym
b
mean
input
cell
f
n
p
n
donor
screen
figur
product
cytokin
includ
interleukin
interleukin
detect
level
similar
control
vst
figur
thu
expans
hmpvreactiv
cell
induc
polyclon
tcell
line
determin
whether
expand
hmpvspecif
cell
cytolyt
cocultur
hmpvspecif
cell
peptideload
autolog
pha
blast
unload
pha
blast
serv
control
shown
figur
hmpvload
target
specif
recogn
lyse
expand
hmpvspecif
cell
effector
target
ratio
test
mean
percentag
lysi
ratio
n
contrast
control
target
cell
kill
mean
percentag
lysi
ratio
final
assess
clinic
relev
hmpvspecif
cell
investig
whether
allogen
hsct
recipi
evid
amplifi
level
cell
direct
identifi
immunodomin
target
antigen
peripher
blood
andor
clearanc
hmpv
infect
figur
show
result
patient
girl
develop
upper
respiratori
tract
infect
day
schedul
receipt
match
relat
donor
transplant
acut
lymphoblast
leukemia
present
symptom
includ
congest
rhinorrhea
cough
hmpv
detect
respiratori
viru
panel
rvp
screen
perform
nasal
wash
sampl
sinc
symptom
resolv
day
transplant
receipt
myeloabl
transplant
proceed
schedul
hmpv
remain
detect
rvp
pcr
day
transplant
assess
whether
reconstitut
hmpvspecif
cell
contribut
viral
clearanc
collect
blood
specimen
week
hsct
receipt
measur
specif
tcell
activ
shown
figur
patient
exhibit
strong
tcell
activ
earli
week
transplant
subsequ
declin
coincid
viral
clearanc
abl
detect
similar
pattern
tcell
activ
addit
transplant
recipi
confirm
hmpv
infect
clear
result
summar
supplementari
tabl
supplementari
figur
studi
character
tcell
immun
respons
viral
encod
hmpv
antigen
base
frequenc
respond
donor
magnitud
reactiv
cell
abl
defin
hierarchi
immunodomin
f
immunogen
follow
descend
order
n
p
l
g
sh
immunogen
reactiv
cell
could
readili
enrich
vitro
polyclon
polyfunct
produc
gmcsf
granzym
b
abl
kill
autolog
antigenload
target
cell
final
potenti
clinic
benefit
follow
adopt
transfer
cell
infer
detect
reactiv
tcell
popul
peripher
blood
allogen
hsct
recipi
success
clear
activ
hmpv
infect
lack
effect
treatment
hmpv
immunocompromis
patient
led
group
investig
potenti
use
adopt
transfer
donorderiv
cell
prevent
andor
treat
hmpv
infect
given
success
approach
clinic
problemat
virus
includ
cytomegaloviru
epsteinbarr
viru
bk
viru
human
herpesviru
adenoviru
thu
first
sought
identifi
appropri
hmpv
antigen
effector
tcell
respons
might
gener
prior
current
studi
limit
inform
immun
hmpv
although
evid
suggest
import
cellmedi
humor
antivir
activ
exampl
immunocompromis
individu
eg
human
immunodefici
patient
steroidtr
hsct
recipi
hmpv
infect
sever
sometim
fatal
treatment
intraven
immunoglobulin
proven
benefici
murin
studi
kolli
et
al
intranas
infect
balbc
mice
laboratori
strain
hmpv
expos
anim
uvinactiv
hmpv
demonstr
deplet
either
cell
compromis
anim
abil
controlclear
viral
challeng
similarli
hast
et
al
vaccin
transgen
mice
either
hmpv
tcell
epitop
irrelev
control
challeng
live
hmpv
strain
demonstr
viral
load
lung
vaccin
anim
significantli
lower
control
mice
final
herd
et
al
demonstr
cell
effector
profil
character
product
prototyp
cytokin
gmcsf
interleukin
proinflammatori
chemokin
macrophag
inflammatori
protein
protein
abl
accumul
lung
follow
hmpv
infect
howev
sinc
immun
studi
human
virus
perform
anim
alway
faith
recapitul
studi
perform
natur
host
sought
analyz
tcell
respons
hmpv
healthi
human
subject
hmpvinfect
hsct
recipi
initi
studi
healthi
adult
discov
frequenc
circul
hmpvreactiv
cell
threshold
detect
assay
elispot
howev
reactiv
cell
could
readili
expand
number
clinic
relev
singl
vitro
stimul
identifi
encod
antigen
induc
protect
immun
took
approach
first
profil
expand
tcell
product
determin
antigen
frequent
recogn
major
donor
screen
healthi
individu
identifi
clear
hierarchi
immunodomin
f
frequent
recogn
follow
n
p
l
g
sh
immunogen
second
examin
peripher
blood
specimen
allogen
hsct
recipi
activ
hmpv
infect
confirm
rvp
pcr
success
clear
hmpv
coincid
amplif
reactiv
cell
subsid
upon
viral
clearanc
final
establish
feasibl
use
adopt
transfer
cell
prophylact
therapeut
approach
immunocompromis
patient
demonstr
hmpvreactiv
cell
effector
profil
success
expand
clinic
relev
number
vitro
mean
manufactur
approach
compliant
good
manufactur
practic
taken
togeth
studi
support
develop
futur
clinic
trial
adopt
transfer
hmpvspecif
cell
specif
either
prophylact
therapeut
use
immunocompromis
patient
